BioXcel Therapeutics (BTAI) Cash from Operations (2017 - 2026)

BioXcel Therapeutics' Cash from Operations history runs 10 years deep, the most recent figure standing at 11809000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 1.94% year-over-year to 11809000.0 in Q1 2026; TTM through Mar 2026 was 57381000.0, a 13.54% increase from a year earlier, with the FY2025 full-year figure at 57615000.0, up 20.01% from the prior year.
• Cash from Operations grew to 11809000.0 in Q1 2026 per BTAI's latest filing, from 14210000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 11809000.0 in Q1 2026 and bottomed at 52353000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 23174000.0 (2024), against an average of 25399882.35.
• Across the five-year window, Cash from Operations sank 93.85% in 2022 and soared 66.18% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 38639000.0 in 2022, then soared by 30.48% to 26863000.0 in 2023, then soared by 44.87% to 14809000.0 in 2024, then advanced by 4.04% to 14210000.0 in 2025, then gained by 16.9% to 11809000.0 in 2026.
• Per Business Quant, the three latest BTAI Cash from Operations figures stand at 11809000.0 (Q1 2026), 14210000.0 (Q4 2025), and 18787000.0 (Q3 2025).